MetaCap

Clearmind Medicine Inc. (CMND)

NASDAQ: CMNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.63-0.5649 (-17.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CMND stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$461.20
52-week range
2.63 – 649.60
Day range
2.63 – 3.28
Volume / Avg
9.84K / 55.57K
Beta
—

52-week range

$2.63$649.60

CMND stock today

Shares of Clearmind Medicine (CMND) finished lower on Nov 20 at $2.63, a drop of 17.68% or $0.5649 per share, versus the S&P 500's 3.70% decline. Trading was light, with 9.84K shares changing hands, about 18% of the average daily volume. At this level, CMND sits near the bottom of its 52-week range of $2.63 to $649.60: 99.6% below the high and 0.0% above the low.

Clearmind Medicine has posted a net loss over the last twelve months (EPS of -$461.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Clearmind Medicine

Company profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Adi Zuloff-Shani Ph.D.
Headquarters
Vancouver, BC

Financial highlights

Full financials

Clearmind Medicine reported a net loss of $3.9 million, compared with a loss of $5.3 million a year earlier. Diluted earnings per share came in at -$30.35.

Clearmind Medicine annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-3.86M$-5.25M$-8.62M$-6.89M$-2.73M
EPS (diluted)$-30.35$-67.80$-1,703.04$-159.11$-88.16

CMND news

All CMND news

Clearmind Medicine peers

Health Care sector
CMND peer companies
CompanyPrice% ChgMarket capCompare
ELABPMGC Holdings Inc.1.14-10.24%$1.33Mvs CMND
CAPSCapstone Holding Corp.1.44-9.15%$1.35Mvs CMND
ARTLArtelo Biosciences Inc.1.39-4.14%$1.30Mvs CMND
APVOAptevo Therapeutics Inc.0.4041-2.37%$1.40Mvs CMND
JUNSJupiter Neurosciences Inc.1.24-18.75%$1.63Mvs CMND
PRFXPRF Technologies Ltd.0.4758-23.68%$1.66Mvs CMND
GOVXGeoVax Labs Inc.1.81-5.24%$985.46Kvs CMND
BDRXBiodexa Pharmaceuticals plc American Depositary Shs1.88-3.85%$982.95Kvs CMND

Indexes, lists and sector

Clearmind Medicine stock FAQ

What is Clearmind Medicine's stock price today?

CMND last traded at $2.63 as of Nov 20, 4:00 PM EST, down 17.68% on the day. Prices are delayed at least 15 minutes.

Who is Clearmind Medicine's CEO?

Dr. Adi Zuloff-Shani Ph.D. is the chief executive officer of Clearmind Medicine Inc..

What is the CMND 52-week high?

The 52-week high for CMND is $649.60 and the 52-week low is $2.63. The stock is currently 99.6% below its high.

Compare CMND